NO933481D0 - QUATERNARY BASIC AMIDS, PROCEDURES FOR PREPARING PRODUCTS AND PHARMACEUTICAL MIXTURES CONTAINING THEM - Google Patents

QUATERNARY BASIC AMIDS, PROCEDURES FOR PREPARING PRODUCTS AND PHARMACEUTICAL MIXTURES CONTAINING THEM

Info

Publication number
NO933481D0
NO933481D0 NO933481A NO933481A NO933481D0 NO 933481 D0 NO933481 D0 NO 933481D0 NO 933481 A NO933481 A NO 933481A NO 933481 A NO933481 A NO 933481A NO 933481 D0 NO933481 D0 NO 933481D0
Authority
NO
Norway
Prior art keywords
group
alkyl
amids
procedures
mixtures containing
Prior art date
Application number
NO933481A
Other languages
Norwegian (no)
Other versions
NO933481L (en
NO304888B1 (en
Inventor
Xavier Emonds-Alt
Patrick Gueule
Vincenzo Proietto
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Publication of NO933481D0 publication Critical patent/NO933481D0/en
Publication of NO933481L publication Critical patent/NO933481L/en
Publication of NO304888B1 publication Critical patent/NO304888B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

The invention relates to basic quaternary amides of formula <IMAGE> in which - Ar represents an optionally substituted mono-, di- or tricyclic heteroaromatic or aromatic group; - T represents a direct bond, a hydroxymethylene group, an alkoxymethylene group in which the alkoxy group is C1-C4 or a C1-C5 alkylene group; - Ar' represents a phenyl which is unsubstituted or substituted one or a number of times, a thienyl, a benzothienyl, a naphthyl or an indolyl; - R represents hydrogen, a C1-C4 alkyl, an omega -(C1-C4)alkoxy(C2-C4)alkyl or an omega -(C1-C4)alkanoyloxy(C2-C 4)alkyl, - Q represents hydrogen; - or else Q and R, together, form a 1,2-ethylene, 1,3-propylene or 1,4-butylene group; - Am<(+)> represents the radical <IMAGE> in which X1, X2 and X3, together and with the nitrogen atom to which they are bonded, form an azabicyclic or azatricyclic system optionally substituted by a phenyl group; - A<(-)> is a pharmaceutically acceptable anion. These compounds are useful in the preparation of medicaments intended for the treatment of pathologies involving the tachykinin system.
NO933481A 1992-09-30 1993-09-29 Quaternary basic amides and pharmaceutical mixtures containing them NO304888B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9212083A FR2696178B1 (en) 1992-09-30 1992-09-30 Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them.

Publications (3)

Publication Number Publication Date
NO933481D0 true NO933481D0 (en) 1993-09-29
NO933481L NO933481L (en) 1994-04-05
NO304888B1 NO304888B1 (en) 1999-03-01

Family

ID=9434374

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933481A NO304888B1 (en) 1992-09-30 1993-09-29 Quaternary basic amides and pharmaceutical mixtures containing them

Country Status (27)

Country Link
EP (1) EP0591040B1 (en)
JP (2) JP2857041B2 (en)
KR (1) KR100279084B1 (en)
CN (1) CN1036652C (en)
AT (1) ATE176469T1 (en)
AU (1) AU674875B2 (en)
BR (1) BR9303982A (en)
CA (1) CA2107432C (en)
CZ (1) CZ287272B6 (en)
DE (1) DE69323375T2 (en)
DK (1) DK0591040T3 (en)
ES (1) ES2130238T3 (en)
FI (1) FI114474B (en)
FR (1) FR2696178B1 (en)
GR (1) GR3030000T3 (en)
HU (2) HU215848B (en)
IL (1) IL107158A0 (en)
MX (1) MX9306024A (en)
MY (1) MY108881A (en)
NO (1) NO304888B1 (en)
NZ (1) NZ248821A (en)
OA (1) OA09869A (en)
RU (1) RU2120436C1 (en)
SG (1) SG47807A1 (en)
SI (1) SI9300513B (en)
TW (1) TW242625B (en)
ZA (1) ZA937276B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583134A (en) * 1992-09-30 1996-12-10 Sanofi 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present
FR2717802B1 (en) * 1994-03-25 1996-06-21 Sanofi Sa New aromatic compounds, process for their preparation and pharmaceutical compositions containing them.
FR2717804B1 (en) * 1994-03-25 1996-06-21 Sanofi Sa Salts of substituted nitrogen heteroaromatic compounds, process for their preparation and pharmaceutical compositions containing them.
EP0694535A1 (en) 1994-04-29 1996-01-31 Eli Lilly And Company Non-peptidyl tachykinin receptor antagonists
AU688072B2 (en) 1994-07-12 1998-03-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2725900B1 (en) * 1994-10-21 1997-07-18 Sanofi Sa USE OF NK1 RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS WITH CARDIOREGULATORY ACTION
GB9421709D0 (en) * 1994-10-27 1994-12-14 Zeneca Ltd Therapeutic compounds
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
CA2162786A1 (en) * 1994-11-22 1996-05-23 Philip Arthur Hipskind Heterocyclic tachykinin receptor antagonists
FR2751654B1 (en) * 1996-07-26 1998-10-23 Sanofi Sa SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2729952B1 (en) * 1995-01-30 1997-04-18 Sanofi Sa SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2729951B1 (en) * 1995-01-30 1997-04-18 Sanofi Sa NOVEL HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2729954B1 (en) * 1995-01-30 1997-08-01 Sanofi Sa SUBSTITUTED HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
AU5951196A (en) * 1995-06-06 1996-12-24 Schering Corporation Substituted benzene-fused hetero- and carbocyclics as neurok inin antagonists
FR2745811B1 (en) * 1996-03-07 1998-05-22 Sanofi Sa DISSUBSTITUTED GLUTARIMIDE PROCESS FOR ITS PREPARATION, AND ITS USE
WO1997044035A1 (en) * 1996-05-24 1997-11-27 Eli Lilly And Company Methods of treating hypertension
US5691362A (en) * 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
GB9617730D0 (en) * 1996-08-23 1996-10-02 Pfizer Ltd Quarternary ammonium compounds
FR2759584B1 (en) * 1997-02-17 1999-06-11 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION OF HETEROCYCLIC COMPOUNDS IN QUATERNARY AMMONIUM FORM
FR2759585B1 (en) * 1997-02-17 1999-06-11 Sanofi Sa PHARMACEUTICAL FORMULATIONS PRESENTED IN A DRY FORM FOR THE ORAL ADMINISTRATION OF A CYCLIC QUATERNARY AMMONIUM COMPOUND
JP2001524960A (en) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist to treat an eating disorder
GB9712882D0 (en) 1997-06-18 1997-08-20 Pfizer Ltd Quaternary ammonium compounds
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
CA2557537A1 (en) * 2004-02-25 2005-09-01 Sankyo Company Limited Sulfonyloxy derivatives
WO2006102308A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1b antagonists
TR201907381T4 (en) 2005-07-19 2019-06-21 Azevan Pharmaceuticals Inc Beta-lactamyl phenylalanine, cysteine and serine vasopressin antagonist.
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
UA105182C2 (en) 2008-07-03 2014-04-25 Ньюрексон, Інк. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
CN107007596A (en) 2010-07-01 2017-08-04 阿泽凡药物公司 Method for treating posttraumatic stress disorder
PL3122743T3 (en) 2014-03-28 2023-05-02 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
KR102278197B1 (en) * 2016-12-14 2021-07-15 베이징 서우바이 파마슈티컬 컴퍼니 리미티드 Bifunctional compound of quaternary ammonium salt structure
MX2020002762A (en) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
FR2666185B1 (en) * 1990-08-21 1992-12-04 Sgs Thomson Microelectronics INTERPOLATION ANALOG / DIGITAL CONVERTER.
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CZ287272B6 (en) 2000-10-11
FI114474B (en) 2004-10-29
JP3243212B2 (en) 2002-01-07
SI9300513A (en) 1994-06-30
DE69323375T2 (en) 1999-06-24
ZA937276B (en) 1994-04-25
EP0591040A1 (en) 1994-04-06
NO933481L (en) 1994-04-05
JP2857041B2 (en) 1999-02-10
JPH10175976A (en) 1998-06-30
AU4870893A (en) 1994-04-14
ATE176469T1 (en) 1999-02-15
IL107158A0 (en) 1993-12-28
HU211889A9 (en) 1995-12-28
FR2696178A1 (en) 1994-04-01
DE69323375D1 (en) 1999-03-18
ES2130238T3 (en) 1999-07-01
CZ203593A3 (en) 1994-04-13
NZ248821A (en) 1995-10-26
CN1036652C (en) 1997-12-10
FI934273A0 (en) 1993-09-29
FI934273A (en) 1994-03-31
HUT65759A (en) 1994-07-28
CN1088582A (en) 1994-06-29
DK0591040T3 (en) 1999-09-20
KR100279084B1 (en) 2001-01-15
CA2107432A1 (en) 1994-03-31
RU2120436C1 (en) 1998-10-20
GR3030000T3 (en) 1999-07-30
HU9302770D0 (en) 1993-12-28
MY108881A (en) 1996-11-30
BR9303982A (en) 1994-10-25
SI9300513B (en) 2002-02-28
NO304888B1 (en) 1999-03-01
KR940007026A (en) 1994-04-26
SG47807A1 (en) 1998-04-17
JPH06211850A (en) 1994-08-02
EP0591040B1 (en) 1999-02-03
FR2696178B1 (en) 1994-12-30
AU674875B2 (en) 1997-01-16
CA2107432C (en) 2000-04-04
HU215848B (en) 1999-04-28
TW242625B (en) 1995-03-11
MX9306024A (en) 1994-03-31
OA09869A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
NO933481D0 (en) QUATERNARY BASIC AMIDS, PROCEDURES FOR PREPARING PRODUCTS AND PHARMACEUTICAL MIXTURES CONTAINING THEM
RU93055131A (en) QUARTERLY AMIDES OF BASIC CHARACTER, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITION
ES2085865T3 (en) DERMORPHINE ANALOGS, THEIR PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC TREATMENT METHODS THAT USE THEM.
UA32525C2 (en) Gastric juice-resistant drug for oral administration containing pantoprazole
GB2193633B (en) Psycho-active pharmaceutical compositions containing indolyl derivatives
WO1990004918A3 (en) Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
DK177890A (en) PHARMACEUTICAL PREPARATION CONTAINING N-ACETYL CYSTEIN FOR ORAL ADMINISTRATION
IT1150213B (en) BIOAVAILABLE IRON DERIVATIVES FREE FROM GASTROLESIVITY, PREPARATION PROCEDURE AND RELATED PHARMACEUTICAL COMPOSITIONS
DK570689D0 (en) PREPARATIONS AND CONNECTIONS
IL44794A0 (en) Pharmaceutical compositions containing certain triazolyl derivatives
DE3269309D1 (en) Pyrrolo(2,3-d)carbazole derivatives, preparation thereof and their therapeutical use
IE872578L (en) Antigestagen compositions
IL87444A0 (en) Pharmaceutical compositions containing polyaromatic compounds
PT82634A (en) Process for preparing novel alkaloid compounds containing a berban skeleton useful as medicaments
IL86096A0 (en) Extended release pharmaceutical compositions containing cholinergic amines
SG135693G (en) Psycho-active pharmaceutical compositions containing indolyl derivatives
GB8306240D0 (en) Pharmaceutical formulations containing azapropazone/indomethacin

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees